Background and objectives: This study examined the abrogative role of Terminalia catappa (T.catappa) leaf aqueous extract (TCLAE) on diabetes-induced dyslipidaemia in obese diabetic rats.Methods: Diabetic animals were induced by fat-rich feed for eight weeks and intraperitoneal streptozotocin (STZ, 30 mg/ kg bw) injection, while glibenclamide (10 mg/kg bw) and TCLAE-graded doses were administered for four weeks.Then, the biomarkers for diabetes, liver function, lipid profile, cardiovascular indices, and liver histology were investigated, in addition to the hepatic expression of some lipid metabolic genes.Results: TCLAE reduced the diabetes-induced fasting blood glucose, weight loss, insulin, alanine transaminase, bilirubin, cholesterol (CHOL), triglyceride (TRIG), low-density lipoprotein-CHOL and -TRIG, high-density lipoprotein-TRIG, atherogenic, coronary risk, and other studied cardiovascular indices.The increase in high-density lipoprotein-CHOL, the upregulation of peroxisome proliferator-activated receptor alpha (PPAR-α), PPAR delta (PPAR-δ), and carnitine palmitoyltransferase 1a, and the downregulation of C-reactive protein (CRP) hepatic gene expression, in addition to the reversal of damaged liver histology, were observed in diabetic rats treated with TCLAE.
No takes yet. Share an insight, caveat, or question.
Iheagwam et al. (2023) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: